Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

GluN1 hypomorph mice exhibit wide-ranging behavioral alterations.

Barkus C, Dawson LA, Sharp T, Bannerman DM.

Genes Brain Behav. 2012 Apr;11(3):342-51. doi: 10.1111/j.1601-183X.2012.00767.x. Epub 2012 Feb 9.

2.

Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.

Enomoto T, Noda Y, Nabeshima T.

Methods Find Exp Clin Pharmacol. 2007 May;29(4):291-301. Review.

PMID:
17609743
3.

Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?

Gandal MJ, Anderson RL, Billingslea EN, Carlson GC, Roberts TP, Siegel SJ.

Genes Brain Behav. 2012 Aug;11(6):740-50. doi: 10.1111/j.1601-183X.2012.00816.x.

4.
5.

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.

Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K.

Nat Neurosci. 2010 Jan;13(1):76-83. doi: 10.1038/nn.2447. Epub 2009 Nov 15.

6.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH.

Arch Gen Psychiatry. 2000 Mar;57(3):270-6.

PMID:
10711913
7.

A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.

Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Möller HJ, Grunze H.

Biol Psychiatry. 2006 Apr 15;59(8):721-9. Epub 2006 Jan 19.

PMID:
16427029
8.

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, Kew JN.

J Neurosci. 2002 Aug 1;22(15):6713-23.

9.

Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes.

Rompala GR, Zsiros V, Zhang S, Kolata SM, Nakazawa K.

PLoS One. 2013 Apr 16;8(4):e61278. doi: 10.1371/journal.pone.0061278. Print 2013.

10.

Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation.

Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ.

Int J Neuropsychopharmacol. 2009 Feb;12(1):45-60. doi: 10.1017/S1461145708009085. Epub 2008 Jul 2.

PMID:
18593507
11.

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK.

Pharmacol Ther. 2010 Dec;128(3):419-32. doi: 10.1016/j.pharmthera.2010.07.004. Epub 2010 Aug 10. Review.

PMID:
20705091
12.

Changes in expression of splice cassettes of NMDA receptor GluN1 subunits within the frontal lobe and memory in mice during aging.

Das SR, Magnusson KR.

Behav Brain Res. 2011 Sep 12;222(1):122-33. doi: 10.1016/j.bbr.2011.03.045. Epub 2011 Apr 2.

13.

Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.

Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL, Blendy JA, Dow HC, Brodkin ES, Schneider F, Gur RC, Siegel SJ.

Genes Brain Behav. 2009 Oct;8(7):661-75. doi: 10.1111/j.1601-183X.2009.00504.x. Epub 2009 May 8.

14.

Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.

Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2181-94. doi: 10.1017/S1461145713000928. Review.

PMID:
24099265
15.

Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders.

Zhou X, Nie Z, Roberts A, Zhang D, Sebat J, Malhotra D, Kelsoe JR, Geyer MA.

Hum Mol Genet. 2010 Oct 1;19(19):3797-805. doi: 10.1093/hmg/ddq298. Epub 2010 Jul 15.

16.

Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome.

Pan D, Sciascia A 2nd, Vorhees CV, Williams MT.

Brain Res. 2008 Jan 10;1188:241-53. Epub 2007 Oct 23.

17.

Reducing expression of GluN1(0XX) subunit splice variants of the NMDA receptor interferes with spatial reference memory.

Das SR, Jensen R, Kelsay R, Shumaker M, Bochart R, Brim B, Zamzow D, Magnusson KR.

Behav Brain Res. 2012 May 1;230(2):317-24. doi: 10.1016/j.bbr.2012.02.014. Epub 2012 Feb 16.

18.

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.

Mohn AR, Gainetdinov RR, Caron MG, Koller BH.

Cell. 1999 Aug 20;98(4):427-36.

19.

Dietary magnesium restriction reduces amygdala-hypothalamic GluN1 receptor complex levels in mice.

Ghafari M, Whittle N, Miklósi AG, Kotlowski C, Schmuckermair C, Berger J, Bennett KL, Singewald N, Lubec G.

Brain Struct Funct. 2015 Jul;220(4):2209-21. doi: 10.1007/s00429-014-0779-8. Epub 2014 May 8. Erratum in: Brain Struct Funct. 2015 Jul;220(4):2223. Kotlowsky, Caroline [Corrected to Kotlowski, Caroline].

PMID:
24807818
20.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039

Supplemental Content

Support Center